Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Matthew Caufield reiterates FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $10 price ...
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued ...
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08052025_FBLG_Bautz.pdf
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and raises the price targ...
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.12) per share which missed the analyst conse...
